DarioHealth (NASDAQ:DRIO) Now Covered by BTIG Research

Stock analysts at BTIG Research started coverage on shares of DarioHealth (NASDAQ:DRIO) in a report released on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $6.00 price target on the stock. BTIG Research‘s target price points to a potential upside of 76.47% from the company’s previous close.

Several other analysts have also recently weighed in on DRIO. Alliance Global Partners started coverage on DarioHealth in a research report on Wednesday, August 19th. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Tuesday, October 6th. Finally, TD Cowen reduced their price objective on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

DarioHealth Stock Down 9.8%

Shares of DRIO stock opened at $3.40 on Tuesday. The firm’s 50 day moving average is $6.30 and its 200 day moving average is $7.97. DarioHealth has a 12 month low of $3.01 and a 12 month high of $16.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31.

DarioHealth (NASDAQ:DRIO) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.37. The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.92 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. As a group, research analysts expect that DarioHealth will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DarioHealth stock. Nantahala Capital Management LLC bought a new position in shares of DarioHealth Corp. (NASDAQ:DRIO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 610,691 shares of the company’s stock, valued at approximately $4,030,561. Nantahala Capital Management LLC owned approximately 8.32% of DarioHealth at the end of the most recent quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

About DarioHealth

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health.

The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.